LRRK2
LRRK2 (leucine rich repeat kinase 2, also known as PARK8, ROCO2 and RIPK7) is a large multidomain serine/threonine kinase with additional GTPase activity. It phosphorylates RAB GTPases and other substrates that govern vesicle trafficking, autophagy, neuronal plasticity and innate immunity. Browse Assay Genie's current range of LRRK2 research reagents below, or read on for the biology behind the target.
LRRK2 is a serine/threonine-protein kinase that phosphorylates a broad range of proteins involved in neuronal plasticity, innate immunity, autophagy and vesicle trafficking. It is a key regulator of RAB GTPases, altering GTP/GDP exchange and the interaction partners of RABs through phosphorylation. Reported RAB substrates include RAB3A, RAB5A, RAB8A, RAB10, RAB12, RAB29, RAB35 and RAB43. Phosphorylation of 'Thr-72' on RAB8A inhibits its interaction with GDI1 and GDI2, and phosphorylation of RAB8A and RAB10 regulates primary ciliogenesis and promotes SHH signalling in the brain.
Beyond RAB signalling, LRRK2 works with RAB29 in retrograde trafficking of recycling proteins such as the mannose-6-phosphate receptor between lysosomes and the Golgi apparatus. It helps recruit SEC16A to endoplasmic reticulum exit sites, positively regulates autophagy through calcium-dependent activation of the CaMKK/AMPK pathway, and phosphorylates APP and PRDX3. In innate immunity it phosphorylates RIPK2 downstream of NOD1 and NOD2, enhancing RIPK2 activation. Independently of its kinase activity, it inhibits proteasomal degradation of MAPT. The Roc domain confers GTPase activity, which in turn regulates kinase activity.
The LRRK2 gene belongs to the leucine-rich repeat kinase family, and the protein sits in the TKL Ser/Thr protein kinase family within the protein kinase superfamily. HGNC places it in the ROCO family. The protein carries ankyrin repeat, leucine-rich repeat, kinase, RAS, GTPase, MLK-like and WD40 domains. It is found largely in the cytoplasm and associates with the mitochondrial outer membrane, among other vesicular and organellar compartments. Mutations in the gene are associated with Parkinson disease-8, which explains the PARK8 alias and the previous name, Parkinson disease (autosomal dominant) 8.
Mutations in the LRRK2 gene are associated with Parkinson disease-8, making it a central protein for studying familial Parkinson disease mechanisms.
LRRK2 phosphorylates multiple RAB GTPases, so it is widely studied for its control of lysosome-Golgi recycling, ER exit sites and synaptic vesicle trafficking.
LRRK2 promotes autophagy through calcium-dependent CaMKK/AMPK signalling and acts at overloaded lysosomes to support lysosomal content release.
By phosphorylating RIPK2 downstream of NOD1 and NOD2, LRRK2 enhances RIPK2 activation and positively regulates innate immunity.
LRRK2 is a serine/threonine kinase that phosphorylates RAB GTPases and other substrates, regulating vesicle trafficking, autophagy, ciliogenesis, neuronal process morphology and innate immunity. It also has GTPase activity through its Roc domain, which regulates its own kinase activity.
LRRK2 is also called PARK8, ROCO2, RIPK7, DKFZp434H2111 and FLJ45829. The PARK8 name and the earlier HGNC name, Parkinson disease (autosomal dominant) 8, reflect the link between mutations in this gene and Parkinson disease-8.
Mouse has an orthologue named Lrrk2. The data supplied do not identify a rat orthologue. For any LRRK2 antibody or ELISA kit, check the datasheet of any product for its validated reactivity.
Other RAB GTPases, innate immune signalling proteins and neurodegeneration-related targets connected with LRRK2 biology.
Gene and protein annotations from HGNC, NCBI Gene and UniProt Q5S007; product specifications from Assay Genie datasheets.